SITC's Cancer Immunotherapy Guidelines program is a
collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
As “living drugs,” the adverse events associated with immune effector cell (IEC) therapy differ markedly from those seen with other anti-cancer regimens. Although IEC-related adverse events are generally manageable with proper supportive care, the toxicities that do occur may have more rapid onset and can progress to life-threatening complications. Therefore, timely recognition and appropriate management of these toxicities are vital for safe use of IEC.
To provide expert guidance to practicing clinicians using IEC therapies and ensure the best outcomes for patients, the SITC established the Immune Effector Cell-related Adverse Expert Panel that included expert perspectives from physicians, nurses, patients, and patient advocates. The Expert Panel is currently developing recommendations for addressing some of the most commonly reported toxicities during treatment with FDA-approved CAR T cell therapies as well as other emerging IEC therapies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and persistent cytopenias and resultant infections, among other key considerations for oncologists treating their patients with these agents. A companion guideline on the management of immune checkpoint inhibitor-related adverse events published on June 25, 2021 in the Journal for ImmunoTherapy of Cancer (JITC).